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Abstract
Background: Acne inversa (AI; also designated as Hidradenitis suppurativa) is a common chronic inflammatory skin disease,
localized in the axillary, inguinal and perianal skin areas that causes painful, fistulating sinuses with malodorous purulence
and scars. Several chronic inflammatory diseases are associated with the metabolic syndrome and its consequences
including arteriosclerosis, coronary heart disease, myocardial infraction, and stroke. So far, the association of AI with
systemic metabolic alterations is largely unexplored.
Methods and Findings: A hospital-based case-control study in 80 AI patients and 100 age- and sex-matched control
participants was carried out. The prevalence of central obesity (odds ratio 5.88), hypertriglyceridemia (odds ratio 2.24), hypo-
HDL-cholesterolemia (odds ratio 4.56), and hyperglycemia (odds ratio 4.09) in AI patients was significantly higher than in
controls. Furthermore, the metabolic syndrome, previously defined as the presence of at least three of the five alterations
listed above, was more common in those patients compared to controls (40.0% versus 13.0%; odds ratio 4.46, 95%
confidence interval 2.02 to 9.96; P,0.001). AI patients with metabolic syndrome also had more pronounced metabolic
alterations than controls with metabolic syndrome. Interestingly, there was no correlation between the severity or duration
of the disease and the levels of respective parameters or the number of criteria defining the metabolic syndrome. Rather,
the metabolic syndrome was observed in a disproportionately high percentage of young AI patients.
Conclusions: This study shows for the first time that AI patients have a high prevalence of the metabolic syndrome and all
of its criteria. It further suggests that the inflammation present in AI patients does not have a major impact on the
development of metabolic alterations. Instead, evidence is given for a role of metabolic alterations in the development of AI.
We recommend monitoring of AI patients in order to correct their modifiable cardiovascular risk factors.
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Introduction
Acne inversa (AI; also referred to as Hidradenitis suppurativa)i sa
chronic, destructive and scarring inflammatory skin disease with a
prevalence of 1 to 4% [1,2]. It mostly affects the intertriginous skin
of perianal, inguinal, and axillary sites, however, submammary,
periumbilical, retroauricular and nuchal sites can also be involved
[3,4]. Initially, infundibular hyperkeratosis and hyperplasia of the
follicular epithelium leads to stasis in the hair follicle unit and
formation of subcutaneous nodules [5]. Already at this early stage,
a perifollicular infiltration of immune cells is present in AI lesions
[6]. Immune cells by means of their mediators probably induce/
enhance the infundibular hyperkeratosis and hyperplasia. Subse-
quently, the nodules rupture and/or meld, forming painful, deep
dermal abscesses [3,4]. The persistence of bacteria in obstructed
and ruptured hair follicles supports the immune cell infiltration
and inflammation and leads to a purulent exudate. In the late-
stage, painful, fistulating sinuses and large indurated inflammatory
plaques with extensive scarring emerge. Without treatment, the
disease is chronic and progressive. AI has a great emotional impact
on patients and causes social embarrassment as well as isolation
[7,8]. Currently, the treatment with the best curative prospect is
the surgical intervention. Small lesions are usually be excised
locally and primary closured [9,10]. Larger lesions require the
radical wide excision of the affected areas followed by reconstruc-
tive intervention [9,11]. The use of antibiotics and tumor necrosis
factor (TNF)-a blockers has been shown to improve symptoms
without ensuring definite cure [12,13,14,15]. Nonetheless, in 15–
35% of patients TNF-a targeting caused long-lasting improvement
($3 months) after the end of the therapy [12,16,17].
The etiology of AI remains enigmatic [3,18]. Smoking, obesity,
hormonal factors and a putative polygenic genetic background
may play a role in its development and/or course. Very recently
we demonstrated that AI lesions show a relative deficiency in the
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cutaneous bacterial persistence and following inflammation of the
affected skin of AI patients [19]. Furthermore, we found in AI
lesions a relative deficiency of interleukin (IL)-22 and IL-20 [19],
two members of the IL-10 cytokine family [20,21,22]. IL-22 and
IL-20 are known to up-regulate anti-microbial protein expression
and are critical for the increase of these molecules under
inflammatory conditions in human epidermis models [19,23].
Interestingly, in AI lesions IL-22 deficiency was associated with
increased IL-10 levels [19]. It seems quite likely that bacteria, the
content of the ruptured hair follicle unit, and TNF-a induce IL-10
which inhibits the lymphocytic IL-22 production. Limited IL-22
production, in turn, leads to limited keratinocyte IL-20 produc-
tion, and the reduced production of both cytokines seems to be
responsible for deficient anti-microbial protein expression. This
allows the bacterial persistence in AI lesions going along with
strong, chronic inflammation and sustained IL-10 production.
Chronic inflammation in defined diseases, such as rheumatoid
arthritis and psoriasis, is associated with metabolic and physiolog-
ical alterations like central obesity, elevated blood pressure,
increased levels of fasting blood glucose, elevated triglyceride
(TG), and reduced high density lipoprotein (HDL)-cholesterol
[24,25,26]. The coincidence of three or more of these abnormal-
ities is called metabolic syndrome. The appearance of the
metabolic syndrome is very important since it increases the risk
of cardiovascular disorders such as arteriosclerosis, coronary heart
disease, myocardial infarction, and stroke, leading to reduced life
expectancy [27,28,29,30]. However, there are no data regarding
the prevalence of different criteria for metabolic syndrome in AI
patients. Thereby, the aim of our current study was to investigate
their frequency in patients suffering from AI.
Methods
Ethics Statement
This study involving human participants was accepted by the
Charite ´ ethics committee (Ethikkommission der Charite ´ Universita ¨tsme-
dizin Berlin). Written informed consent was obtained from all study
participants.
Study population
We performed a hospital-based case - control study with 80
patients suffering from AI and 100 control participants from the
area around Berlin. All those AI patients were enrolled in the
study, who (i) visited the Department of Dermatology, University
Hospital Charite ´, Berlin, Germany, (ii) gave written informed
consent, and (iii) fulfilled the following inclusion criteria: age of at
least 18 years, absence of any malignant disorder, no previous
treatment with immunosuppressive agents. As control participants
were enrolled individuals who (i) replied to our announcement
(e.g. via internet and posters) for the search of study participants,
(ii) gave written informed consent, (iii) were older than 18 years
and were matching in age and sex with the AI patients, and (iv)
had never been diagnosed with AI and were not immunocom-
promised or diagnosed with any malignant disorder.
After obtaining informed consent, clinical data were collected
(age, gender, weight, height, waist circumference, blood pressure,
and history of illness). The body mass index (BMI) was calculated
as weight (kg)/[height (m)]
2. The waist circumference was
measured at the level of the most upper part of the hipbone
without compression on the skin. Blood pressure was measured
after a 5 minute rest in sitting position. Venous fasting blood was
taken for investigation of plasma glucose, triglycerides (TG), and
HDL.
AI was clinically diagnosed according to the following criteria:
(i) typical lesions, i.e. deep-seated painful nodules: ‘blind boils’
in early lesions; abscess, draining sinus, bridged scars and
‘tombstone’ open comedones in secondary lesions,
(ii) typical topography, i.e. in axillae, groin, perineal and
perianal regions, buttocks,
(iii) persistence and recurrence of lesions.
The severity of AI was measured by the ‘Sartorius Score’ [31]
from the axillary and inguinal region as follows:
(i) anatomical region involved (axillary or inguinal region). 3
points per involved region,
(ii) number and scores of lesions (abscesses, nodules, fistulas,
scars or others). 2 points for each nodule, 4 points for each
fistula, 1 point for each scar, 1 point for each ‘‘other’’,
(iii) the longest distance between 2 relevant lesions, i.e. nodules
and fistulas, in each region, or size if only 1 lesion. 2 points
if ,5 cm; 4 points if 5 to 10 cm; 8 points if .10 cm,
(iv) if lesions were clearly separated by normal skin in each
region: 0 points; if not: 6 points.
The metabolic syndrome was diagnosed in the presence of three
or more of the following criteria, according to the US National
Cholesterol Education Program Adult Treatment Panel III
(NCEP-ATP III) [32]:
(i) central obesity: waist circumference $102 cm (male),
$88 cm (female),
(ii) hypo-HDL-cholesterolemia: plasma HDL-cholesterol
,40 mg/dl (male), ,50 mg/dl (female),
(iii) hypertriglyceridemia: plasma triglyceride $1.695 mmol/l
($150 mg/dl),
(iv) hypertension: blood pressure $130/85 mmHg or use of
medication for hypertension,
(v) hyperglycemia: fasting plasma glucose $6.1 mmol/L
($110 mg/dl) or use of medication for hyperglycemia.
Statistical analysis
Standard descriptive statistics such as mean, standard deviation
(SD), and standard error of the mean (SEM) were computed.
Further statistical calculations were made using SPSS 14.0
software (SPSS). Results from AI patients and control participants
were compared using the Mann–Whitney U test (two-tailed) or
Chi-square test. P-values,0.05 were considered to be statistically
significant. Correlation analysis was performed between severity of
Table 1. Demographic characteristics of AI patients and
controls.
AI patients Controls P-value
Males (%) 46.3% 44.0% 0.763
Females (%) 53.7% 56.0% 0.763
Age in years
(mean 6 SD) 40.0610.6 40.9610.5 0.639
(range) 21–62 20–63
The P-values calculated by the Chi-square test (sex distribution) or Mann–
Whitney U test (age) are indicated.
doi:10.1371/journal.pone.0031810.t001
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syndrome criteria, and separate diagnostic parameters of meta-
bolic syndrome by means of Spearman’s rank correlation analysis.
Results
In our current study we investigated the levels of metabolic
syndrome parameters and the prevalence of fulfilled respective
criteria in 80 patients suffering from AI and compared these to
results from 100 respective control participants. As a prerequisite
for these analyses, there were no differences in age and sex
between these two groups. In fact, the sex ratio was approximately
1:1, and their average age was ,40 years in both cohorts
(Table 1).
In the patient group, the disease duration and the Sartorius
scores had a rather wide range, namely from 1 to 41 years and
from 12 to 84, respectively (Table S1), which facilitated the
analysis of the possible interrelation between these parameters and
the magnitude of various metabolic alterations. The mean disease
duration was 11 years in male and 13 years in female AI patients.
The average Sartorius score was about 35 in both male and female
patients. Roughly one half of the patients never had any surgical
intervention at the time of enrolment.
The quantification of metabolic syndrome parameters in AI
patients and controls uncovered that average waist circumference,
plasma TG levels, fasting plasma glucose levels, as well as the
systolic and diastolic blood pressure were significantly higher in AI
patients than in control participants (Figure 1, Table S2).
Furthermore, the average plasma HDL levels were lower in AI
patients. Even more importantly, the prevalence of central obesity
(odds ratio 5.88; 95% confidence interval, 2.93 to 11.91,
P,0.001), hypertriglyceridemia (odds ratio 2.24; 95% confidence
interval, 1.11 to 4.54, P,0.014), hypo-HDL-cholesterolemia (odds
ratio 4.56; 95% confidence interval, 2.21 to 9.46, P,0.001), and
hyperglycemia (odds ratio 4.09; 95% confidence interval, 1.59 to
10.84, P,0.001) in AI patients were significantly higher than in
control participants (Figure 1, Table S2). Finally, the metabolic
syndrome was significantly more common in the patients than in
controls (40.0% versus 13.0%, P,0.001, odds ratio 4.46; 95%
confidence interval, 2.02 to 9.96) (Figure 1, Table S2).
Additionally, 20% of all AI patients (half of the AI patients with
metabolic syndrome) compared to only 5% of all controls (38.5%
of controls with metabolic syndrome) were positive for more than
three of the metabolic syndrome-defining criteria (Figure 2) and,
therefore, had an even higher risk for cardiovascular diseases [27].
The analysis of subgroups such as overweight individuals
(BMI$25) demonstrated that the prevalence of metabolic
syndrome and its parameters were significantly higher in
respective patients than in respective controls (for metabolic
syndrome 50.8% versus 25.6%, P,0.01, odds ratio 3.01; 95%
confidence interval, 1.18 to 7.76) (Figure 3). We also observed a
two times higher prevalence of metabolic syndrome in smoking AI
patients compared to smoking control participants (data not
shown). However, because the smoking controls are a small
population whereas about 90% of AI patient are smokers, further
investigations are necessary to support this conclusion.
These results raised the question about the mechanisms
underlying the increased frequency of the metabolic syndrome
in AI patients. The simplest hypothesis may be that the chronic
inflammation present in AI patients promotes and enhances
metabolic alterations. If this hypothesis was correct then the
severity and/or duration of disease would positively correlate with
the magnitude of the metabolic alterations. To test this, we
analyzed the correlation between the severity and duration of the
illness and the waist circumference, plasma TG and HDL levels,
diastolic and systolic blood pressure, fasting plasma glucose levels,
and the number of fulfilled criteria for metabolic syndrome.
Surprisingly, no significant correlations between the analyzed
parameters were found (Figure 4, Table 2). Furthermore, we did
not find any significant correlations between the levels of analyzed
parameters and the age at AI diagnosis (Table 2). Next, we
subdivided the AI patients in two subgroups, namely those with
Figure 1. Parameter levels and frequency of fulfilled criteria for metabolic syndrome in AI patients and control persons. (A) The
average waist circumference, plasma HDL-cholesterol and TG levels, systolic and diastolic blood pressure, and fasting plasma glucose levels in AI
patients and control participants are demonstrated as the mean 6 SEM. Significance of differences was assessed by the Mann–Whitney U-test
(*P,0.05, **P,0.01, ***P,0.001). (B) The frequency of central obesity, hypo-HDL-cholesterolemia, hypertriglyceridemia, hypertension, hyperglycemia
in AI patients and controls are given. Significance of differences was assessed by the Chi-square test (*P,0.05, **P,0.01, ***P,0.001). (C) The
percentages of AI patients and controls with metabolic syndrome are given. Significance of differences was assessed by the Chi-square test
(**P,0.01).
doi:10.1371/journal.pone.0031810.g001
Figure 2. Percentages of AI patients and control participants that fulfilled the indicated number of metabolic syndrome criteria. The
dashed vertical line marks the cutoff for the metabolic syndrome.
doi:10.1371/journal.pone.0031810.g002
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Sartorius scores and duration of AI with each plasma TG levels and the number of positive metabolic syndrome criteria was investigated by
Spearman’s rank correlation analysis. No significant correlation was found.
doi:10.1371/journal.pone.0031810.g004
Figure 3. Frequency of fulfilled criteria for metabolic syndrome in overweight and obese AI patients and control participants. The
frequency of central obesity, hypo-HDL-cholesterolemia, hypertriglyceridemia, hypertension, hyperglycemia in AI patients (n=59) and controls
(n=43) with a BMI of 25 or higher are given. Significance of differences was assessed by the Chi-square test (*P,0.05, ***P,0.001).
doi:10.1371/journal.pone.0031810.g003
Acne Inversa and Metabolic Syndrome
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31810relatively mild disease (Sartorius score ,30; n=39) and those with
severe symptoms (Sartorius score .30; n=41). Again, there was
no difference in the levels of metabolic parameters and no
difference in the prevalence of central obesity, hypertriglyceride-
mia, hypo-HDL-cholesterolemia, arterial hypertension, hypergly-
cemia, or metabolic syndrome between these two groups (data not
shown).
Because of this unexpected finding we started further analysis
and explored the possibility whether surgical treatment with
reduction of the inflammatory load might reduce manifestations of
Table 3. Criteria and parameters of metabolic syndrome in pre-operative and post-operative patients suffering from AI.
Pre-operative
AI patients
Post-operative
AI patients P-value
Waist circumference (cm)
female 100.4616.3 94.8616.7 0.542
male 98.1625.0 112.0618.7 0.009
Central obesity (%) 57.9% 71.4% 0.207
Plasma HDL-cholesterol (mg/dl)
female 49.5617.8 51.0619.5 0.836
male 39.067.1 45.2615.3 0.505
Hypo-HDL-cholesterolemia (%) 55.3% 45.2% 0.370
Plasma TG (mmol/l) 152.3695.7 162.7692.6 0.424
Hypertriglyceridemia (%) 36.8% 40.5% 0.739
Blood pressure (mm Hg)
diastolic 79.566.3 80.069.0 0.860
systolic 121.767.7 123.0614.2 0.744
Hypertension (%) 44.7% 50.0% 0.638
Fasting plasma glucose (mmol/l) 101.4631.2 91.3618.2 0.161
Hyperglycemia (%) 23.7% 28.6% 0.620
BMI (kg/m
2)2 9 . 1 67.6 30.267.3 0.458
Metabolic syndrome (%) 34.2% 45.2% 0.315
Sartorius score 39.0615.2 31.0613.4 0.014
The percentages of pre-operative and post-operative patients with pathological alterations (%) and mean 6 SD data of the analyzed parameters are shown. The P-
values calculated by the Mann–Whitney U-test (for waist circumference, plasma HDL-cholesterol, plasma TG, blood pressure, fasting plasma glucose) or thy Chi-square
test (for frequency of central obesity, hypo-HDL-cholesterolemia, hypertriglyceridemia, hypertension, hyperglycemia, and metabolic syndrome) are indicated. Significant
P-values (,0.050) are in boldface.
doi:10.1371/journal.pone.0031810.t003
Table 2. Correlation of severity and duration of AI with parameters of metabolic syndrome.
Sartorius score Duration Age at AI diagnosis
Waist circumference (cm) 0.060
(0.600)
20.082
(0.470)
0.011
(0.924)
Plasma HDL-cholesterol (mg/dl) 20.072
(0.527)
0.118
(0.299)
0.142
(0.208)
Plasma TG (mmol/l) 20.048
(0.673)
0.058
(0.609)
0.124
(0.275)
Diastolic blood pressure (mmHg) 0.196
(0.082)
0.052
(0.644)
0.007
(0.949)
Systolic blood pressure (mm Hg) 0.143
(0.205)
20.034
(0.764)
0.056
(0.621)
Fasting plasma glucose (mmol/l) 0.079
(0.486)
20.032
(0.776)
20.063
(0.582)
BMI (kg/m
2) 0.172
(0.128)
20.100
(0.379)
20.118
(0.299)
Number of fulfilled metabolic syndrome criteria 0.042
(0.711)
0.050
(0.663)
20.101
(0.663)
The correlation was investigated by Spearman’s rank correlation analysis. For each field, the Spearman’s rank correlation coefficient and, in parenthesis, the P-values are
indicated.
doi:10.1371/journal.pone.0031810.t002
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criteria for metabolic syndrome and the levels of respective
parameters in 38 patients that never had surgical intervention (pre-
operative patients) and versus 42 patients that already had at least
one surgical intervention (post-operative patients). There were no
significant differences in sex, age, and duration of disease between
these two groups (Table S3). As expected, the Sartorius score was
lower in the post-operative group as compared to the pre-
operative group. However, no differences for any of the criteria for
the metabolic syndrome between both groups could be detected
(Table 3). To substantiate this finding, we analyzed details about
further 12 patients (5 males, 7 females) who had their last surgical
intervention averagely 4 years ago (199615 weeks). Although
these patients had no or minimal disease activity, their current
BMI had remained unchanged compared to values before surgery
(26.8 versus 26.3). All these data suggest that the inflammation
present in AI patients does not have any major impact on their
metabolic alterations.
In the last part of our study we questioned which AI patients are
particularly endangered by the metabolic syndrome. The
frequency of the metabolic syndrome usually increases with
increasing age of a population. Surprisingly, we found no
significant correlation between the patients’ age and the number
of fulfilled metabolic syndrome criteria or between the age and
respective parameter levels even if such correlations clearly existed
in our control population (Figure 5A, Table 4). In order to
understand the cause of the non-existing correlations with the age
in AI patients, we subdivided these patients and controls into three
age groups: #34-year-olds, 35 to 44-year-olds, and $45-year-olds,
and determined the prevalence of metabolic syndrome in each
group. By doing so we surprisingly found no differences between
these three age groups in AI patients. Rather, in contrast to the
control participants, already very young AI patients were detected
to suffer from the metabolic syndrome (Figure 5B). In fact, the
odds ratios for the prevalence of metabolic syndrome calculated
for each age group of AI patients were: .20 (#34-year-olds), 6.18
(35 to 44-year-olds), and 1.97 ($45-year-olds), even if they were
based on small groups (between 22 and 41 persons per group).
These data provided strong evidence that the appearance of the
metabolic syndrome affects a disproportionately high number of
young AI patients.
Discussion
In our current study we investigated the prevalence of the
metabolic syndrome in patients suffering from AI and demon-
strated for the first time a significantly higher frequency of
metabolic syndrome in such patients compared to age- and sex-
Figure 5. Correlation between age and metabolic syndrome for AI patients and control participants. (A) The correlation of age with the
number of fulfilled metabolic syndrome criteria was investigated by Spearman’s rank correlation analysis for AI patients and controls. Significant
correlation was found only for controls (Spearman’s rank correlation coefficient rs=0.363, ***P,0.000). (B) The prevalence of the metabolic syndrome
in AI patients and control participants in different age groups is given (#34 years old AI patients: n=22; #34 years old control participants: n=36; 35
to 44 years old AI patients: n=27, 35 to 44 years old control participants: n=23; $45 years old AI patients: n=31; $45 years old control participants:
n=41). Significance of differences was assessed by the Chi-square test (*P,0.05, ***P,0.001).
doi:10.1371/journal.pone.0031810.g005
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hypo-HDL-cholesterolemia, hypertriglyceridemia, and hypergly-
cemia was also significantly elevated in AI patients. Finally, the
average waist circumference, plasma TG levels, fasting plasma
glucose levels, as well as the systolic and diastolic blood pressure
were significant higher, and average plasma HDL levels were
lower in AI patients than in control participants.
Commonly, these metabolic and physiological alterations
increase the risk of coronary heart disease, myocardial infarction,
and stroke leading to reduced life expectancy [27,28,29,30]. That
implies that 40% of our AI patients are considerably endangered
by these cardiovascular diseases. This is of particular importance
since the endangering also affects very young AI patients. In fact,
approximately 40% of our AI patients that were younger than 35
years suffered from metabolic syndrome compared to 0% of
respective age- and sex-matched controls (odds ratio .20). In the
age group between 35 and 44 years the difference, although being
slightly lower, was still very high (odds ratio 6.18). We believe that
an important message of our study is that clinicians who treat AI
patients take into consideration that (i) a large portion of their
patients have metabolic problems that are indicated neither by the
Sartorius score nor by the duration of the disease, but that need to
be addressed and (ii) that even very young AI patients are affected
with this.
Increased prevalence of the metabolic syndrome is also known
from patients suffering from some other chronic inflammatory
diseases, e.g., psoriasis [33]. However, there seem to be certain
differences between psoriasis and AI in this regard. First, the
prevalence of metabolic disturbances [34,35] and metabolic
syndrome [26,36] in AI patients appears to be higher than in
psoriasis patients. For example, Love et al. very recently showed
for populations of psoriasis patients and controls, which, regarding
age and sex, were comparable to our cohort, a prevalence of
metabolic syndrome of 31.4% and 17.1%, respectively, and an
odds ratio of 2.22 [36]. Second, in psoriasis [26] but not in AI
patients there was an association between disease duration and
metabolic syndrome appearance and between at least some
criteria of the metabolic syndrome and the severity of the disease.
Third, the metabolic syndrome preferentially affects psoriasis
patients at a mostly higher age [26], whereas many young AI
patients are concerned. Thereby, the consequences of metabolic
alterations for AI patients could be even markedly worse than for
psoriasis patients, for whom increased mortality from cardiovas-
cular diseases has been documented [37].
After finding that AI patients suffer more frequently from the
metabolic syndrome we asked for the underlying mechanism. To
test the possibility that the chronic inflammation induces metabolic
disturbances in these patients, we correlated Sartorius score and
duration of disease with individual parameters for metabolic
syndrome. Surprisingly, no significant correlation was found.
Interestingly, with the exception of the Sartorius score we also did
not detect significant differences regarding metabolic alterations
between AI patients who never had surgical intervention versus
those after relevant surgical therapy. All these facts suggest that
chronic inflammation is not the major driver of the metabolic
alterations in AI patients. Based on our results we speculate that
the metabolic alterations might be the primary rather than a
secondary pathological event in these patients, i.e., that they might
trigger AI. In fact, the metabolic alterations can lead to poor blood
circulation of respective skin areas. Hypoxia in turn induces IL-10
production in CD4+ T-cells [38], and IL-10 inhibits the
production of IL-22 [19], an important inducer of keratinocyte
IL-20 production [19,39]. Since IL-22 and IL-20 are major
inducers of antibacterial proteins in epithelia [23,40,41], poor
blood circulation would eventually lead to enhanced cutaneous
bacterial persistence and the outbreak of AI. This hypothesis
should be investigated by future studies.
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Table 4. Correlation of different parameters of metabolic
syndrome with the age of AI patients and controls.
AI patients Controls
Waist circumference (cm) 0.050
(0.661)
0.433
(0.000)
Plasma HDL-cholesterol (mg/dl) 0.235
(0.036)
20.126
(0.213)
Plasma TG (mmol/l) 0.171
(0.129)
0.166
(0.099)
Diastolic blood pressure (mm Hg) 0.094
(0.406)
0.261
(0.009)
Systolic blood pressure (mmHg) 0.113
(0.319)
0.261
(0.009)
Fasting plasma glucose (mmol/l) 20.051
(0.652)
0.331
(0.001)
BMI (kg/m
2) 20.111
(0.327)
0.353
(0.000)
Number of fulfilled metabolic syndrome criteria 0.012
(0.916)
0.363
(0.000)
The correlation was investigated by Spearman’s rank correlation analysis. For
each field, the Spearman’s rank correlation coefficient and, in parenthesis, the P-
values are indicated. Significant P-values (,0.050) are in boldface.
doi:10.1371/journal.pone.0031810.t004
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